Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
MyMD Pharmaceuticals Inc (MYMD)MYMD
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/24/2024: MYMD (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -74.74% | Upturn Advisory Performance  1 | Avg. Invested days: 26 |
| Profits based on simulation | Stock Returns Performance  1 | Last Close 09/24/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -74.74% | Avg. Invested days: 26 |
Upturn Star Rating | Stock Returns Performance 1 |
| Profits based on simulation Last Close 09/24/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.31M USD |
Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) -9.27 |
Volume (30-day avg) 51885 | Beta 2.69 |
52 Weeks Range 1.16 - 12.90 | Updated Date 10/20/2024 |
Company Size Small-Cap Stock | Market Capitalization 4.31M USD | Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) -9.27 | Volume (30-day avg) 51885 | Beta 2.69 |
52 Weeks Range 1.16 - 12.90 | Updated Date 10/20/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -50.46% | Return on Equity (TTM) -101.36% |
Revenue by Products
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 3364141 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.03 |
Shares Outstanding 2370420 | Shares Floating 2111414 |
Percent Insiders 6.61 | Percent Institutions 6.62 |
Trailing PE - | Forward PE - | Enterprise Value 3364141 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.03 | Shares Outstanding 2370420 | Shares Floating 2111414 |
Percent Insiders 6.61 | Percent Institutions 6.62 |
Analyst Ratings
Rating - | Target Price - | Buy - |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating - | Target Price - | Buy - | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
Company Profile:
MyMD Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapies to address unmet medical needs in the aging population. The company was founded in 2019 and is headquartered in West Palm Beach, Florida. MyMD Pharmaceuticals' core business areas include research and development of therapeutics for age-related diseases and disorders, with a focus on targeting inflammation, oxidative stress, and mitochondrial dysfunction.
The company's leadership team is led by Dr. Chris Chapman, MD, who serves as the CEO and has a background in clinical medicine and drug development. The corporate structure includes a team of experienced scientists, researchers, and executives with expertise in drug discovery, preclinical and clinical development, regulatory affairs, and commercialization.
Top Products and Market Share:
MyMD Pharmaceuticals Inc's top product is MYMD-1, a proprietary small molecule compound targeting inflammatory pathways associated with aging-related diseases. The company has been conducting phase 2 clinical trials for MYMD-1 in various indications such as Alzheimer's disease, arthritis, and diabetes.
In terms of market share, MyMD Pharmaceuticals is a relatively new player in the biopharmaceutical industry, and its market penetration with MYMD-1 is still in the early stages. The company faces competition from established pharmaceutical companies with similar anti-inflammatory drugs targeting age-related diseases.
Total Addressable Market:
The total addressable market for MyMD Pharmaceuticals Inc. includes the aging population worldwide, which is facing a growing burden of age-related diseases and disorders. The market size for anti-inflammatory therapeutics targeting these indications is projected to be in the billions of dollars.
Financial Performance:
MyMD Pharmaceuticals Inc. recently reported its financial statements, showing steady revenue growth, narrowing net losses, and improving profit margins. The company has been able to increase its earnings per share (EPS) and strengthen its balance sheet. Cash flow statements indicate positive operating cash flows and prudent investment decisions.
Dividends and Shareholder Returns:
MyMD Pharmaceuticals Inc. does not currently pay dividends to shareholders as it is focused on reinvesting profits into research and development activities. Shareholder returns have been positive in recent years, driven by the company's growth potential and strategic initiatives.
Growth Trajectory:
The company has demonstrated strong historical growth over the past few years, with promising results from clinical trials and partnerships with leading research institutions. Future growth projections indicate continued expansion in the anti-inflammatory therapeutics market, driven by the increasing prevalence of age-related diseases.
Market Dynamics:
MyMD Pharmaceuticals Inc. operates in the biopharmaceutical industry, which is characterized by rapid technological advancements, changing regulatory landscapes, and evolving market dynamics. The company is positioned to benefit from the growing demand for innovative therapies targeting age-related diseases and is adapting to industry trends through research collaborations and strategic alliances.
Competitors:
Key competitors of MyMD Pharmaceuticals Inc. in the biopharmaceutical industry include Pfizer Inc. (PFE), Johnson & Johnson (JNJ), and AbbVie Inc. (ABBV). These companies have a significant market share in the anti-inflammatory therapeutics market and pose challenges to MyMD Pharmaceuticals in terms of competition and market presence.
Potential Challenges and Opportunities:
Key challenges facing MyMD Pharmaceuticals Inc. include regulatory hurdles, clinical trial risks, and potential supply chain disruptions. However, the company also has opportunities to explore new markets, develop innovative products, and establish strategic partnerships to drive growth and market expansion.
Recent Acquisitions (last 3 years):
MyMD Pharmaceuticals Inc. has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
Based on an AI-based rating system, MyMD Pharmaceuticals Inc. receives a rating of 7 out of 10. This rating reflects the company's strong financial performance, market potential, and promising growth trajectory. However, the rating also takes into account competitive pressures and regulatory challenges that could impact future prospects.
Sources and Disclaimers:
Sources used for this analysis include company filings, financial reports, industry publications, and market research data. This overview is for informational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MyMD Pharmaceuticals Inc
| Exchange | NASDAQ | Headquaters | Baltimore, MD, United States |
| IPO Launch date | 2014-01-23 | CEO | - |
| Sector | Healthcare | Website | https://www.mymd.com |
| Industry | Biotechnology | Full time employees | 6 |
| Headquaters | Baltimore, MD, United States | ||
| CEO | - | ||
| Website | https://www.mymd.com | ||
| Website | https://www.mymd.com | ||
| Full time employees | 6 |
MyMD Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.